NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY)

Clinical trials for NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY) explained in plain language.

Never miss a new study

Get alerted when new NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY) trials appear

Sign up with your email to follow new studies for NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First human trial tests 'Rejuvenating' gene therapy for blinding eye diseases

Disease control Recruiting now

This is the first study in people to test the safety of a new gene therapy called ER-100 for two conditions that damage the optic nerve and cause vision loss: open-angle glaucoma and NAION. Researchers will give a single dose to 18 adults and closely monitor them for side effects…

Matched conditions: NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY)

Phase: PHASE1 • Sponsor: Life Biosciences Inc. • Aim: Disease control

Last updated Mar 25, 2026 14:07 UTC

NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY)

Get alerted when new NAION( NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY) trials appear

First human trial tests 'Rejuvenating' gene therapy for blinding eye diseases